BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• BioNTech has positioned itself as a biopharmaceutical company with multiple programs in late-stage clinical development

  80% confidence

• Positive clinical trial results could pave the way for multiple short- and medium-term product launches, bringing BioNTech closer to helping patients with various cancer types

  80% confidence

• BioNTech expects at least 17 late-stage clinical data readouts through 2030 and beyond, including from registration-enabling studies, to inform decisions on multiple potential product launches and establish BioNTech as a multi-product oncology company by 2030

  80% confidence

• BioNTech plans to start six additional Phase 3 clinical trials in 2026, bringing total expected Phase 3 trials to 15 by year-end

  80% confidence

• BioNTech currently expects no revenues from oncology product sales in 2026

  80% confidence

• 2026 is a year when scientific progress becomes tangible results for BioNTech, with milestones including late-stage data releases, early clinical trial results for combination therapies, and launch of additional Phase 3 trials

  80% confidence

• BioNTech closed 2025 with strong momentum through consistent execution in R&D, partnerships, acquisitions, and strong financial position while advancing next wave of innovations including combination studies

  80% confidence

• BioNTech expects collaboration revenues from Bristol Myers Squibb partnership in 2026 to be essentially at 2025 levels

  80% confidence

• BioNTech expects moderate decline in Comirnaty revenues in 2026 compared to 2025, reflecting current COVID-19 vaccine market dynamics influenced by changing vaccination recommendations especially in the United States and transition from multi-year contracts to private markets

  80% confidence

Data points we hold from this source

Cité dans ces articles de Via News

• China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →